In this case report we describe a novel treatment with two chimeric monoclonal antibodies (MoAb) targeting the autoimmune B cell clone responsible for bullous pemphigoid (BP) as a manifestation of steroid refractory chronic graft-versus-host disease (GVHD) that developed after unrelated cord blood transplantation. Monitoring the BP-specific circulating antibodies and CD25-expressing activated T lymphocyte subset led us to combine anti-CD20 (Rituximab) mediated B cell ablation with anti-CD25 (Daclizumab) therapy to block CD4 + T cell help. Complete clinical and serologic response was achieved within 4 weeks of initiation of therapy allowing global immunosuppression to be dramatically reduced. Bone Marrow Transplantation (2002) 30, 327-329. doi:10.1038/sj.bmt.1703654 Keywords: transplantation; GVHD; bullous pemphigoid; rituximab; daclizumab A 10-year-old boy was diagnosed with B-precursor ALL at 18 months of age. After 6 months of treatment he had CNS recurrence followed shortly by a bone marrow relapse. He received standard chemotherapy for 3 years with craniospinal irradiation. Four years off therapy he sustained a second isolated bone marrow relapse. During chemotherapy he was noted to have a testicular relapse that was treated with involved-field irradiation and additional chemotherapy. He was in his fourth remission when he arrived at our center.
A 10-year-old boy was diagnosed with B-precursor ALL at 18 months of age. After 6 months of treatment he had CNS recurrence followed shortly by a bone marrow relapse. He received standard chemotherapy for 3 years with craniospinal irradiation. Four years off therapy he sustained a second isolated bone marrow relapse. During chemotherapy he was noted to have a testicular relapse that was treated with involved-field irradiation and additional chemotherapy. He was in his fourth remission when he arrived at our center.
Following total body irradiation (1350 cGy total), 3 days of melphalan (135 mg/m 2 total) and ATG (90 mg/kg total) he was transplanted with an O+, male, 4/6 HLA-matched unrelated umbilical cord blood graft in March 1999 and engrafted with full donor chimerism. The patient and donor were mismatched at one HLA-A and HLA-DRB1 loci, respectively. He received cyclosporin A and solumedrol for GVHD prophylaxis.
During the first 3 months post transplant the patient experienced pancreatitis, acute renal failure secondary to rhabdomyolysis, and pulmonary hemorrhage. He developed grade 3 acute GVHD of the gut 5 weeks after transplant that was controlled with steroids, FK506, and 10 weeks of anti-CD25 monoclonal antibody (daclizumab). The patient had multiple readmissions for pulmonary edema and respiratory failure secondary to renal insufficiency and hemolytic uremic syndrome that continued to require intermittent hemodialysis. Four months after transplant he was readmitted with hypertensive encephalopathy presumed secondary to FK-506 toxicity. While FK-506 was discontinued he developed GVHD of the skin, controlled by the combination of steroids and the addition of azathioprine and mycophenolate mofetil.
Despite continued immunosuppressive therapy with mycophenolate mofetil at 30 mg/kg/day and methylprednisolone at 1 mg/kg/day (Table 1), 7 months after transplant pruritic hemorrhagic bullae developed over his entire body. Skin biopsy of a bulla revealed a subepidermal blister with spongiosis, and hemorrhagic infiltration of lymphocytes, and eosinophils. Direct immunofluorescence of tissue sections revealed linear deposits of IgG and C3 at the basement membrane. Indirect immunofluorescence (IDIF) on 1 m NaCl split skin 1 revealed a linear band of IgG bound to the epidermal side of the split skin. Immunoprecipitation studies showed that the patient's serum contained IgG with strong reactivity to BPAG2, and faint reactivity to BPAG1 thus confirming bullous pemphigoid (BP) as a manifestation of his chronic GVHD (Figure 1 ).
The lesions failed to respond to further increases of his steroid dose to 2 mg/kg/day. His skin transiently improved during a 3-week course of OKT3, but by the third week new lesions occurred. To better characterize his skin disease, four-color immunofluorescent staining of his circulating lymphocytes was compared with immunohistochemical stains of skin sections. IDIF showed circulating IgG against epidermal side of split skin at a titer of у1:2560. A striking circulating B cell lymphocytosis (559/l) was noted while CD3
+ cells were spuriously absent presumably secondary . Subconfluent monolayers of cultured human keratinocytes were biosynthetically radiolabeled with 35S-methionine (50 Ci/ml, specific activity 1100 Ci/mmol (Du Pont New England Nuclear Research Products, Boston, MA, USA)) for 2 h. Radiolabeled cell extracts were processed as described previously 1 and studied by immunoprecipitation using sera from our patient, reference controls with bullous pemphigoid (positive controls), or a normal volunteer (negative control). Immunoprecipitation samples were applied to gradient Tris-glycine gels (Novex, San Diego, CA, USA) and studied by fluorography.
to reduced CD3 expression immediately after OKT3 therapy (Table 1) .
In view of his B cell lymphocytosis and the laboratory evidence for antibody-mediated disease, humanized monoclonal antibody anti-CD20 (rituximab) was started at 375 mg/m 2 /dose i.v., weekly ϫ4 doses. Over the next 10 days his skin condition worsened with lesions covering his entire body. While B cells rapidly disappeared as tested before the second dose of rituximab a concomitant surge of CD25 + CD4 + T cells was detected in his peripheral blood as T lymphocytes rebounded from OKT3 treatment ( Table 1) . A brief steroid pulse together with a course of humanized anti-CD25 monoclonal antibody (daclizumab) therapy was initiated at 1 mg/kg/dose on days 1, 4, 8 and weekly thereafter in order to interrupt CD4 + T cell help. No new lesions were noted after 1 week and a complete response was reached in 4 weeks. Clinical response was accompanied by the immediate disappearance of CD25 + T cells and a gradual decline in BP titers below detectable (Table 1) . Daclizumab was discontinued after 10 weeks of therapy while steroids and mycophenolate mofetil were slowly weaned.
As a sign of potentially imminent recurrence a single bulla developed over the left foot 2 months off daclizumab, which was accompanied by a rise in his BP titer (у1:320) and an elevated percentage (31%) of CD25 + T cells (Table 1 ). There were almost no circulating B cells (9/l) and, over 95% of his T cells were CD4 + , suggesting that CD20-negative plasma cells activated by CD25 + CD4 + T cells had resumed secretion of the pathogenic BPAG2-specific antibody (Table 1, Figure 1 ). In view of the rising BP titers along with emerging CD25 co-expressing CD4 + T cells, another course of daclizumab was started at 1 mg/kg/dose weekly. This time the patient responded to daclizumab alone without the need to increase steroids or mycophenolate. Over the subsequent 12 months, while continuing to receive weekly anti-CD25, the patient remained in clinical and serologic remission tolerating weaning of some of his immunosuppression (Table 1) . Unfortunately he died a year later in clinical remission due to bacterial sepsis with progressive renal failure on chronic dialysis.
Discussion
Anti-CD20 antibody (rituximab) is a chimeric mouse /human, IgG 1 kappa antibody that mediates complementdependent cell lysis and antibody-dependent cellular cytotoxicity. 2 While developed for the treatment of B cell malignancies, it also has efficacy in the treatment of chronic autoimmune diseases. Successful treatment of ITP in a patient with chronic GVHD has been reported with rituximab alone. 3 It has also been shown to be effective in other autoimmune syndromes with successes reported in ITP, 4, 5 autoimmune hemolytic anemias, 6 and pure red cell aplasia. 7 In this report we describe the first use of rituximab to treat BP, as a manifestation of chronic GVHD of the skin. Rituximab alone caused prompt removal of circulating CD20 + B cells after the first dose (Table 1 ), but our patient progressed clinically while also receiving significant amounts of steroids and mycophenolate mofetil. The addition of anti-CD25 therapy was necessary to achieve a complete clinical response and a decrease in the disease-specific antibody titers. We believe anti-CD25 was required for the observed response because it interrupted the helper function of CD4 + T cells facilitating the secretion of antibodies against BPAG2 (Figure 1, Table 1 ) by CD20 negative plasma cells. Daclizumab has proven clinical efficacy in preventing T cell-mediated organ transplant rejection 8 and has shown promise in the treatment of acute GVHD. 9 To our knowledge this is the first reported combination treatment of monoclonal antibodies targeting T cell-dependent B cell diseases, such as BP. Careful trials with laboratory monitoring are warranted to explore the potential of such immunomodulatory combination therapy designed to avoid global immunosuppression and organ toxicities in patients with antibody-mediated autoimmune diseases.
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